University Collaboration

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) is expanding its *ai^² Futures Lab* program through a collaboration with the University of Oregon’s Lundquist College of Business, starting Winter 2026. This initiative connects student teams with biopharmaceutical business development projects, aiming to discover therapeutic assets and nurture future industry leaders. Students will assess early-stage pharmaceutical assets, analyze markets and intellectual property, and identify pathways for patient care. The program, part of Apimeds’ *ai^²* innovation platform, also partners with the University of Alabama and the University of San Diego.